Benzinga | May 5, 2021 08:17AM EDT

Morgan Stanley Maintains Equal-Weight on Esperion Therapeutics, Lowers Price Target to $22

Morgan Stanley maintains Esperion Therapeutics (NASDAQ:ESPR) with a Equal-Weight and lowers the price target from $30 to $22.